Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$978M |
| 2 |
Microsoft
MSFT
|
+$812M |
| 3 |
Bank of America
BAC
|
+$602M |
| 4 |
Apple
AAPL
|
+$518M |
| 5 |
NVIDIA
NVDA
|
+$412M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.32B |
| 2 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$1.12B |
| 3 |
State Street Communication Services Select Sector SPDR ETF
XLC
|
+$958M |
| 4 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$940M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$816M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.45% |
| 2 | Financials | 11.83% |
| 3 | Healthcare | 11.27% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 7.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3526
iShares MSCI Indonesia ETF
EIDO
$480M
| $82.4K | ﹤0.01% |
3,700
| – | – |
|
3527
Defiance Quantum ETF
QTUM
$5.23B
| $81.5K | ﹤0.01% |
1,700
| – | – |
|
3528
Five Star Bancorp
FSBC
$1.14B
| $81.5K | ﹤0.01% |
4,064
-341
| -8% | -$7.62K |
|
3529
Ocular Therapeutix
OCUL
$1.79B
| $81.5K | ﹤0.01% |
25,963
+4,840
| +23% | +$19.8K |
|
3530
Costamare
CMRE
$1.88B
| $81.4K | ﹤0.01% |
8,463
-1,166
| -12% | -$11.9K |
|
3531
Invesco NASDAQ Internet ETF
PNQI
$528M
| $81.1K | ﹤0.01% |
2,645
| – | – |
|
3532
C4 Therapeutics
CCCC
$385M
| $81.1K | ﹤0.01% |
43,614
+10,246
| +31% | +$31.3K |
|
|
TGB
3533
Trekor Metals
TGB
$2.48B
| $80.8K | ﹤0.01% |
63,653
+3,536
| +6% | +$4.89K |
|
3534
Organogenesis Holdings
ORGO
$305M
| $80.4K | ﹤0.01% |
25,276
+11,284
| +81% | +$35.9K |
|
3535
NWPX Infrastructure Inc
NWPX
$1.19B
| $80.2K | ﹤0.01% |
2,657
+692
| +35% | +$21.8K |
|
3536
Quantum-Si Incorporated
QSI
$155M
| $79.6K | ﹤0.01% |
47,938
-1,839
| -4% | -$4.43K |
|
3537
First Community Corp
FCCO
$321M
| $79.5K | ﹤0.01% |
4,604
-14
| -0.3% | -$249 |
|
|
VCXB
3538
DELISTED
10X Capital Venture Acquisition Corp III
VCXB
| $79.2K | ﹤0.01% |
7,400
| – | – |
|
|
HUT
3539
Hut 8
HUT
$12.1B
| $79K | ﹤0.01% |
8,105
+106
| +1% | +$1.5K |
|
|
SRDX
3540
DELISTED
Surmodics
SRDX
| $77.6K | ﹤0.01% |
2,417
-322
| -12% | -$10.9K |
|
3541
Protalix BioTherapeutics
PLX
$191M
| $77.2K | ﹤0.01% |
46,511
+33,281
| +252% | +$59.7K |
|
3542
Atea Pharmaceuticals
AVIR
$376M
| $76.9K | ﹤0.01% |
25,619
+10,348
| +68% | +$35.2K |
|
3543
Orange County Bancorp
OBT
$513M
| $76.8K | ﹤0.01% |
3,560
-180
| -5% | -$3.93K |
|
|
OPTN
3544
DELISTED
OptiNose
OPTN
| $76.8K | ﹤0.01% |
4,163
-121
| -3% | -$2.18K |
|
|
CRON
3545
Cronos Group
CRON
$1.06B
| $76.7K | ﹤0.01% |
38,325
+468
| +1% | +$915 |
|
|
LL
3546
DELISTED
LL Flooring Holdings, Inc.
LL
| $76.5K | ﹤0.01% |
24,140
-8,154
| -25% | -$29.3K |
|
3547
USCB Financial Holdings
USCB
$406M
| $76.3K | ﹤0.01% |
7,257
-604
| -8% | -$6.7K |
|
3548
Westrock Coffee
WEST
$792M
| $76K | ﹤0.01% |
8,577
-1,171
| -12% | -$12.2K |
|
3549
Butterfly Network
BFLY
$1.89B
| $76K | ﹤0.01% |
64,386
+11,112
| +21% | +$21.5K |
|
3550
Velocity Financial
VEL
$689M
| $75.9K | ﹤0.01% |
6,718
-255
| -4% | -$3.1K |
|
Similar funds
Barclays's Q3 2023 Portfolio in Review
As of Q3 2023, Barclays held 4,832 positions worth $161B, up 1.7% from $158B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Barclays deployed $8.05B of net new capital in Q3 2023, opening 336 new positions and adding to 1,838 existing holdings. Its largest new stake was CRH: 17,203,754 shares worth $942M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $1.32B trimmed.
- Barclays's largest Q3 2023 buy was CRH: 17,203,754 shares worth $942M.
- Barclays added most to Microsoft in Q3 2023, an estimated $812M increase.
- Barclays's biggest Q3 2023 reduction was Invesco QQQ Trust, cutting an estimated $1.32B.
- Barclays fully exited Aerojet Rocketdyne Holdings in Q3 2023, selling an estimated $154M.
- Barclays's ten largest holdings make up 24% of its $161B portfolio in Q3 2023.
- Barclays opened 336 new positions and closed 249 in Q3 2023.
- Barclays's portfolio value rose 1.7% quarter-over-quarter to $161B.
Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.